155 related articles for article (PubMed ID: 26749281)
1. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
[TBL] [Abstract][Full Text] [Related]
2. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
[TBL] [Abstract][Full Text] [Related]
3. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].
Wang Q; Zhong M; Lü YL; Yuan J; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):603-6. PubMed ID: 23157828
[TBL] [Abstract][Full Text] [Related]
5. The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to
Bar JK; Lis-Nawara A; Grelewski P; Noga L; Grzebieniak Z; Jeleń M
Anticancer Res; 2017 Sep; 37(9):4953-4960. PubMed ID: 28870917
[TBL] [Abstract][Full Text] [Related]
6. RAS status in Korean patients with stage III and IV colorectal cancer.
Lee WS; Lee JN; Baek JH; Park YH
Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
[TBL] [Abstract][Full Text] [Related]
7. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
11. Factor inhibiting HIF1α (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1α pathway.
Chen T; Ren Z; Ye LC; Zhou PH; Xu JM; Shi Q; Yao LQ; Zhong YS
Cancer Biol Ther; 2015; 16(2):244-52. PubMed ID: 25602156
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1).
Chen T; Yao LQ; Shi Q; Ren Z; Ye LC; Xu JM; Zhou PH; Zhong YS
Cancer Biol Ther; 2014 May; 15(5):516-23. PubMed ID: 24521875
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis, necroptosis and autophagy in colorectal cancer: Associations with tumor aggressiveness and p53 status.
Sakanashi F; Shintani M; Tsuneyoshi M; Ohsaki H; Kamoshida S
Pathol Res Pract; 2019 Jul; 215(7):152425. PubMed ID: 31097354
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
[TBL] [Abstract][Full Text] [Related]
15. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
16. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
17. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
Veldore VH; Rao MR; Prabhudesai SA; Tejaswi R; Kakara S; Pattanayak S; Krishnamoorthy N; Tejaswini BN; Hazarika D; Gangoli A; Rahman SM; Dixit J; Naik R; Diwakar RB; Satheesh CT; Shashidhara HP; Patil S; Gopinath KS; Kumar BS
Indian J Cancer; 2014; 51(4):531-7. PubMed ID: 26842186
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
Ohta M; Seto M; Ijichi H; Miyabayashi K; Kudo Y; Mohri D; Asaoka Y; Tada M; Tanaka Y; Ikenoue T; Kanai F; Kawabe T; Omata M
Gastroenterology; 2009 Jan; 136(1):206-16. PubMed ID: 18992247
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Features and Survival Rate of Colorectal Adenocarcinoma Patients with and without a KRAS Mutation: a FiveYear Study in Yazd, Iran.
Zahir ST; NazemianYazdi M; Arasteh P; Mortazavizadeh M; Karbalaeian M; ZareMehrjardi M
Asian Pac J Cancer Prev; 2016; 17(7):3417-22. PubMed ID: 27509985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
